TRIGR Therapeutics Completes $14 Million Seed Round and Provides Phase 1a Clinical Update on its Lead Bispecific Oncology Candidate, TR009
IRVINE, CA / ACCESSWIRE / March 25, 2019 / TRIGR Therapeutics, Inc. (''TRIGR''), a newly formed privately held company focused...